Clinical trials: Epilepsy, Partial
Seizure Disorder, Partial
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
- Trial name
- NCT00141245
- Testing
- Pregabalin
- Where
- 46 sites in Australia, Austria and 11 more
- Volunteers
- 325 people
- Sponsor
- Pfizer
Epilepsy
Pediatric Epilepsy Trial in Subjects 1-24 Months
This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures.
- Trial name
- NCT00043875
- Testing
- lamotrigine
- Where
- 65 sites in United States, Australia and 12 more
- Volunteers
- 177 people
- Sponsor
- GlaxoSmithKline
Partial Epilepsies
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects…
- Trial name
- NCT00955357
- Testing
- Lacosamide
- Where
- 109 sites in United States, Austria and 13 more
- Volunteers
- 461 people
- Sponsor
- UCB Pharma
Epilepsy, Dravet Syndrome
A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome
Dravet Syndrome (DS) is a severe neurodevelopmental disease, which is predominantly caused by mutations of SCN1A, the gene coding for Nav1.1 voltage-gated sodium channels.
- Conditions
- Epilepsy, Dravet Syndrome, Drug Resistant Epilepsy, Healthy Controls
- Trial name
- DRAPETONINE (NCT07013331)
- Testing
- [18F]MPPF PET-MRI
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Partial Seizures
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration…
- Trial name
- PREPS MEXICO (NCT00407797)
- Testing
- Pregabalin
- Where
- 8 sites in Mexico
- Volunteers
- 136 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Epilepsy
Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to…
- Trial name
- NCT00900237
- Testing
- Eslicarbazepine acetate, Oxcarbazepine
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Epilepsies, Partial
Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)
There are no guidelines on the first maintenance daily dose of antiepileptic drugs (AEDs) in newly diagnosed, previously untreated epilepsy.
- Trial name
- STANDLOW (NCT03689114)
- Testing
- Low dose carbamazepine, Standard dose carbamazepine, Low dose levetiracetam
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Epilepsy, Partial Epilepsy
Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients
This is a post-market medical device study. This study will compare best medical practice with or without adjunctive VNS Therapy in patients who are 16 years and older with pharmacoresistant partial epilepsy.
- Trial name
- NCT00522418
- Testing
- Vagal Nerve Simulation (VNS) Therapy, Best Medical Practive
- Where
- 48 sites in Belgium, Canada and 8 more
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Cyberonics, Inc.
Focal Epilepsy
Efficacy and Safety of Rapid Titration Protocols of Lacosamide
Three different dose titration schedules are tested to find a way to reduce the titration period of lacosamide
- Trial name
- NCT03607851
- Testing
- Lacosamide - conventional titration, Lacosamide - rapid titration 1, Lacosamide - rapid titration 2
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Seoul National University Hospital
Tinnitus, Epilepsy, Temporal Lobe
Pathophysiology, Psycho-emotional and Cognitive Functioning Associated With Tinnitus
the investigators have recently shown that patients with drug-resistant temporal lobe epilepsy who have undergone brain surgery targeting the medial temporal lobe structures were more likely to develop tinnitus postoperatively.
- Trial name
- AudiCog (NCT04717388)
- Testing
- acoustics tests, Questionaries,, MRI
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Partial Epilepsy
Cenobamate Expanded Access Program (EAP)
This Cenobamate Expanded Access Program (EAP) is designed to continue providing treatment with Cenobamate (YKP3089) to patients with partial-onset epilepsy that were enrolled in the SK Life Science clinical trial YKP3089C013…
- Trial name
- NCT04513860
- Testing
- YKP3089
- Sponsor
- SK Life Science, Inc.
Epilepsy, Epilepsies, Partial
Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
The purpose of this study is to assess a possible predictor for weight loss seen in epilepsy patients treated with topiramate.
- Conditions
- Epilepsy, Epilepsies, Partial, Epilepsy, Generalized, Seizures
- Trial name
- NCT00236886
- Testing
- topiramate
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
This is a multicentre, open label study to examine the effect of ezogabine/retigabine on the voiding function of adult subjects with drug-resistant partial onset seizures (POS).
- Trial name
- NCT01607346
- Testing
- ezogabine/retigabine
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Focal Epilepsy
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
- Trial name
- NCT07238868
- Testing
- CB03-154
- Where
- Australia
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Psychogenic Seizure, Epilepsy, Temporal Lobe
Self-modulation of the Sense of Agency by Means of Real-time Neurofeedback
This study investigates whether the sense of agency is sensitive to self-regulation by means of EEG-based neurofeedback. During neurofeedback, the brain activity in response to a motor task is recorded in real-time and displayed…
- Conditions
- Psychogenic Seizure, Epilepsy, Temporal Lobe, Health, Subjective
- Trial name
- NF-Agency (NCT05214833)
- Testing
- Real Neurofeedback
- Where
- Switzerland
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- ETH Zurich
Pain, Arm
The Effects of Three Different Techniques During PIVC
Purpose: This study will conducted to the effect of three different techniques used during peripheral intravenous cannulation (PIVC) application on vein visibility, pain and comfort in cancer patients receiving palliative care.
- Conditions
- Pain, Arm, Visual Aura, Infrared; Rays, Injury
- Trial name
- NCT05847816
- Testing
- Experimental group: infrared vascular imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Ege University
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Epilepsies, Partial
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
- Trial name
- NCT00448916
- Testing
- Pregabalin
- Where
- 18 sites in United States, Mexico and 1 more
- Volunteers
- 54 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsy
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the…
- Trial name
- NCT00310375
- Testing
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Where
- 51 sites in United States, Argentina and 3 more
- Volunteers
- 181 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector